Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation.

PURPOSE Delays to adjuvant chemotherapy initiation in breast cancer may adversely affect clinical outcomes and patient satisfaction. We previously identified an association between genomic testing (Onco type DX) and delayed chemotherapy initiation. We sought to reduce the interval between surgery and adjuvant chemotherapy initiation by developing standardized criteria and workflows for Onco type DX testing. METHODS Criteria for surgeon-initiated reflex Onco type DX testing, workflows for communication between surgeons and medical oncologists, and a streamlined process for receiving and processing Onco type DX requests in pathology were established by multidisciplinary consensus. Criteria for surgeon-initiated testing included patients ≤ 65 years old with T1cN0 (grade 2 or 3), T2N0 (grade 1 or 2), or T1/T2N1 (grade 1 or 2) breast cancer on final surgical pathology. Medical oncologists could elect to initiate Onco type testing for cases falling outside the criteria. We then examined 720 consecutive patients with breast cancer who underwent Onco type DX testing postoperatively between January 1, 2014 and November 28, 2016 and measured intervals between date of surgery, Onco type DX order date, result received date, and chemotherapy initiation date (if applicable) before and after intervention implementation. RESULTS The introduction of standardized criteria and workflows reduced time between surgery and Onco type DX ordering, and time from surgery to receipt of result, by 7.3 days ( P < .001) and 6.3 days ( P < .001), respectively. The mean number of days between surgery and initiation of chemotherapy was also reduced by 6.4 days ( P = .004). CONCLUSION Developing consensus on Onco type DX testing criteria and implementing streamlined workflows has led to clinically significant reductions in wait times to chemotherapy decision making and initiation.

[1]  W. Valentine,et al.  Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  N. Lin,et al.  Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  M. Somerfield,et al.  Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations Summary. , 2016, Journal of oncology practice.

[4]  J. Beck,et al.  Time to Surgery and Breast Cancer Survival in the United States. , 2016, JAMA oncology.

[5]  W. Gradishar,et al.  NCCN Guidelines Update: Breast Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  E. Scarpi,et al.  Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. , 2015, European journal of cancer.

[7]  Gregory Katz,et al.  Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France , 2015, PloS one.

[8]  L. Steuten,et al.  Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective. , 2015, Journal of comparative effectiveness research.

[9]  Jama Oncology Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer , 2015 .

[10]  D. Winchester,et al.  Wait Times for Breast Surgical Operations, 2003–2011: A Report from the National Cancer Data Base , 2015, Annals of Surgical Oncology.

[11]  R. Gelber,et al.  Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Hortobagyi,et al.  Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Keda Yu,et al.  Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis , 2013, BMC Cancer.

[14]  C. Lohrisch Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions , 2013 .

[15]  M. Castiglione,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Rayson,et al.  Wait times for breast cancer care , 2006, British Journal of Cancer.

[18]  K. Gelmon,et al.  Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Smith,et al.  Does timing of adjuvant chemotherapy for early breast cancer influence survival? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Philip Smith,et al.  The influence on survival of delay in the presentation and treatment of symptomatic breast cancer , 1999, British Journal of Cancer.